Commentary|Articles|October 2, 2014
Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
Author(s)Sandra M. Swain, MD, FACP, FASCO
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.
Advertisement
Clinical Pearls
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study. This study looked at first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
- Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm – a different of 15.7 months.
- The standard first line treatment for patients with HER2-positive metastatic breast cancer should be pertuzumab, trastuzumab, and a taxane.
- In practice, community oncologists could use paclitaxel instead of docetaxel.
<<<
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5